3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
14
Leukemia, Myeloid, Acute
7
Neoplasms
3
Neoplasm Metastasis
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neuroblastoma
2
Liver Neoplasms
2
Hepatoblastoma
2
Fibrolamellar hepatocellular carcinoma
2
Tongue Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Sarcoma, Myeloid
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
1
Melanoma
1
Gastrointestinal Stromal Tumors
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
25
Cisplatin
23
Carboplatin
18
Magnetic Resonance Spectroscopy
16
Paclitaxel
15
Specimen Handling
14
Pemetrexed
11
durvalumab
9
Radiotherapy, Intensity-Modulated
8
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Nivolumab
7
Radiation
6
Docetaxel
6
Cetuximab
6
Biopsy
6
osimertinib
5
cemiplimab
5
Taxes
5
Radiotherapy
5
Ipilimumab
5
Cyclophosphamide
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
poly ICLC
4
cabozantinib
4
atezolizumab
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Sorafenib
×
1 year
×
Clear all
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts